HK1201519A1 - 磷酸二酯酶第 型的抑制劑 - Google Patents

磷酸二酯酶第 型的抑制劑

Info

Publication number
HK1201519A1
HK1201519A1 HK15101856.4A HK15101856A HK1201519A1 HK 1201519 A1 HK1201519 A1 HK 1201519A1 HK 15101856 A HK15101856 A HK 15101856A HK 1201519 A1 HK1201519 A1 HK 1201519A1
Authority
HK
Hong Kong
Prior art keywords
inhibitors
phosphodiesterase type
phosphodiesterase
type
Prior art date
Application number
HK15101856.4A
Other languages
English (en)
Inventor
Herv Geneste
Michael Ochse
Karla Drescher
Sean Turner
Berthold Behl
Loic Laplanche
Jrgen Dinges
Clarissa Jakob
Lawrence A Black
Katja Jantos
Original Assignee
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1201519(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Deutschland filed Critical Abbvie Deutschland
Publication of HK1201519A1 publication Critical patent/HK1201519A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HK15101856.4A 2011-11-09 2015-02-23 磷酸二酯酶第 型的抑制劑 HK1201519A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161557874P 2011-11-09 2011-11-09
PCT/EP2012/072150 WO2013068470A1 (en) 2011-11-09 2012-11-08 Inhibitors of phosphodiesterase type 10a

Publications (1)

Publication Number Publication Date
HK1201519A1 true HK1201519A1 (zh) 2015-09-04

Family

ID=47178004

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101856.4A HK1201519A1 (zh) 2011-11-09 2015-02-23 磷酸二酯酶第 型的抑制劑

Country Status (25)

Country Link
US (3) US20130116241A1 (zh)
EP (1) EP2776418B1 (zh)
JP (1) JP2014534976A (zh)
KR (1) KR20140097318A (zh)
CN (1) CN104053654A (zh)
AR (1) AR088801A1 (zh)
AU (1) AU2012334074A1 (zh)
BR (1) BR112014011284A2 (zh)
CA (1) CA2852604A1 (zh)
CL (1) CL2014001212A1 (zh)
CO (1) CO7030959A2 (zh)
CR (1) CR20140223A (zh)
DO (1) DOP2014000097A (zh)
ES (1) ES2620531T3 (zh)
GT (1) GT201400089A (zh)
HK (1) HK1201519A1 (zh)
IL (1) IL232358A0 (zh)
MX (1) MX2014005714A (zh)
PE (1) PE20141938A1 (zh)
RU (1) RU2014123316A (zh)
SG (1) SG11201402142VA (zh)
TW (1) TW201326153A (zh)
UY (1) UY34445A (zh)
WO (1) WO2013068470A1 (zh)
ZA (1) ZA201402966B (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9200005B2 (en) 2013-03-13 2015-12-01 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
EA201591962A1 (ru) 2013-05-10 2016-06-30 Нимбус Аполло, Инк. Ингибиторы акк и их применение
EP2994139B1 (en) 2013-05-10 2019-04-10 Gilead Apollo, LLC Acc inhibitors and uses thereof
US9765089B2 (en) * 2013-05-10 2017-09-19 Gilead Apollo, Llc ACC inhibitors and uses thereof
AU2014262636A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
WO2014200882A1 (en) 2013-06-11 2014-12-18 Janssen Pharmaceutica Nv PDE10a INHIBITORS FOR THE TREATMENT OF TYPE II DIABETES
WO2014200885A1 (en) * 2013-06-11 2014-12-18 Janssen Pharmaceutica Nv PDE10a INHIBITORS FOR THE TREATMENT OF TYPE II DIABETES
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
US10005764B2 (en) * 2014-04-04 2018-06-26 H. Lundbeck A/S Halogenated quinazolin-THF-amines as PDE1 inhibitors
RU2659070C9 (ru) * 2014-04-23 2018-08-24 Дарт Нейросайенс (Кайман) Лтд. ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
GB201416352D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
US9840491B2 (en) 2015-02-05 2017-12-12 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
WO2016126935A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
US9932351B2 (en) 2015-02-05 2018-04-03 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
EP3317277B1 (en) 2015-07-01 2021-01-20 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
JOP20180114B1 (ar) 2016-06-22 2022-09-15 Univ Vanderbilt عوامل تعديل متباينة التجاسم موجبة من مستقبل الأسيتيل كولين المسكاريني m4
BR112018013882A2 (pt) 2016-11-07 2018-12-18 Vanderbilt University moduladores alostéricos positivos do receptor muscarínico de acetilcolina m4
WO2018085808A1 (en) 2016-11-07 2018-05-11 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
MA46899A (fr) 2016-11-07 2021-04-14 Univ Vanderbilt Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
CN108084199A (zh) * 2017-06-13 2018-05-29 长沙理工大学 一种合成呋喃并[3,2-c]吡啶-4(5H)-酮衍生物的方法
US11028068B2 (en) 2017-07-25 2021-06-08 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
CN111108105B (zh) 2017-09-22 2023-03-31 朱比兰特埃皮帕德有限公司 作为pad抑制剂的杂环化合物
SG11202003463XA (en) 2017-10-18 2020-05-28 Jubilant Epipad LLC Imidazo-pyridine compounds as pad inhibitors
CA3080677A1 (en) 2017-11-06 2019-05-09 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
IL274762B2 (en) 2017-11-24 2023-10-01 Jubilant Episcribe Llc Novel heterocyclic compounds as PRMT5 inhibitors
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
WO2019113174A1 (en) 2017-12-05 2019-06-13 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
JP2021519786A (ja) 2018-03-30 2021-08-12 バイオセリックス， インコーポレイテッド チエノピリミジノン化合物
AR127621A1 (es) * 2021-11-09 2024-02-14 Vigil Neuroscience Inc Compuestos heterocíclicos como agonistas del receptor activador expresado en células mieloides 2 y métodos de uso

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03120857A (ja) * 1989-10-04 1991-05-23 Ibiden Co Ltd 電子部品塔載装置
AU7238191A (en) * 1990-02-19 1991-09-03 Chugai Seiyaku Kabushiki Kaisha Novel fused heterocyclic compound and antiasthmatic agent prepared therefrom
US5380721A (en) * 1990-09-10 1995-01-10 Sterling Winthrop Inc. Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents
JP3245165B2 (ja) 1991-10-09 2002-01-07 シンテックス（ユー・エス・エイ）・インコーポレイテッド ピリドピリダジノンおよびピリダジンチオン化合物
CA2104060A1 (en) 1992-11-10 1994-05-11 Robert Ed Johnson Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents
CN1045962C (zh) * 1993-01-01 1999-10-27 森德克斯(美国)股份有限公司 吡啶并哒嗪酮或吡啶并哒嗪硫酮化合物,制备它的中间体,含它的药物组合物及其用途
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
AU6964096A (en) 1995-09-15 1997-04-01 Pharmacia & Upjohn Company Aminoaryl oxazolidinone n-oxides
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
US20030166476A1 (en) 2002-01-31 2003-09-04 Winemiller Mark D. Lubricating oil compositions with improved friction properties
CA2534432A1 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
US7307163B2 (en) 2004-04-19 2007-12-11 Symed Labs Limited Process for the preparation of linezolid and related compounds
CA2568929A1 (en) 2004-06-07 2005-12-22 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
DE602004020812D1 (de) 2004-07-20 2009-06-04 Symed Labs Ltd Neue zwischenprodukte für linezolid und verwandte verbindungen
AU2005282721A1 (en) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
EP1940819A1 (en) 2005-08-16 2008-07-09 Memory Pharmaceuticals Corporation Phosphodiesterase 10 inhibitors
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
WO2007082546A1 (en) 2006-01-20 2007-07-26 H. Lundbeck A/S Use of tofisopam as a pde10a inhibitor
BRPI0707223A2 (pt) 2006-01-27 2011-04-26 Pfizer Prod Inc compostos de derivados de aminoftalazina
EP1991530A1 (en) 2006-02-21 2008-11-19 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
CA2643983A1 (en) 2006-02-21 2007-08-30 Amgen, Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
JP2009527542A (ja) 2006-02-23 2009-07-30 ファイザー・プロダクツ・インク Ｐｄｅ１０阻害薬としての置換キナゾリン
EP1991531A1 (en) 2006-02-28 2008-11-19 Amgen Inc. Cinnoline and quinoxaline derivates as phosphodiesterase 10 inhibitors
US20070265258A1 (en) 2006-03-06 2007-11-15 Ruiping Liu Quinazoline derivatives as phosphodiesterase 10 inhibitors
JP2009529060A (ja) 2006-03-08 2009-08-13 アムゲン インコーポレイティッド ホスホジエステラーゼ１０阻害剤としてのキノリン及びイソキノリン誘導体
TW200815436A (en) 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
WO2008001182A1 (en) 2006-06-26 2008-01-03 Pfizer Products Inc. Tricyclic heteroaryl compounds as pde10 inhibitors
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
US8492394B2 (en) 2006-07-10 2013-07-23 H. Lundbeck A/S (3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl-thiomorpholin-4-yl) derivatives of 6,7-dialkoxy-quinazoline, 6,7-dialkoxyphtalazine and 6,7-dialkoxyisoquinoline as PDE10A enzyme inhibitors
WO2008020302A2 (en) * 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
WO2008098857A1 (en) 2007-02-15 2008-08-21 F. Hoffmann-La Roche Ag 2-aminooxazolines as taar1 ligands
EP2148867B1 (en) 2007-04-19 2014-09-10 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009025823A1 (en) 2007-08-21 2009-02-26 Amgen Inc. Phosphodiesterase 10 inhibitors
WO2009025839A2 (en) 2007-08-22 2009-02-26 Amgen Inc. Phosphodiesterase 10 inhibitors
WO2009029214A1 (en) 2007-08-23 2009-03-05 Amgen Inc. Isoquinolone derivatives as phosphodiesterase 10 inhibitors
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
TW200918519A (en) 2007-09-19 2009-05-01 Lundbeck & Co As H Cyanoisoquinoline
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
JP2010540635A (ja) 2007-10-02 2010-12-24 コンサート ファーマシューティカルズ インコーポレイテッド ピリミジンジオン誘導体
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
WO2009051782A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
CA2703591C (en) 2007-10-26 2013-05-07 Concert Pharmaceuticals, Inc. Deuterated darunavir
US7875618B2 (en) 2007-11-30 2011-01-25 Wyeth Substituted imidazo[1,5-a]quinoxalines useful as inhibitors of phosphodiesterase 10 for the treatment of neurological and other disorders
WO2009068246A2 (en) 2007-11-30 2009-06-04 Elbion Gmbh Methods of treating obesity and metabolic disorders
WO2009068320A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
US20090143361A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
US20130116241A1 (en) * 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a

Also Published As

Publication number Publication date
EP2776418A1 (en) 2014-09-17
US20160137668A1 (en) 2016-05-19
CA2852604A1 (en) 2013-05-16
ES2620531T3 (es) 2017-06-28
US9657034B2 (en) 2017-05-23
CR20140223A (es) 2014-09-09
CO7030959A2 (es) 2014-08-21
ZA201402966B (en) 2017-08-30
UY34445A (es) 2013-06-28
CN104053654A (zh) 2014-09-17
EP2776418B1 (en) 2017-01-04
PE20141938A1 (es) 2014-12-28
BR112014011284A2 (pt) 2017-05-02
US20130116241A1 (en) 2013-05-09
DOP2014000097A (es) 2014-07-15
US20130116233A1 (en) 2013-05-09
RU2014123316A (ru) 2015-12-20
SG11201402142VA (en) 2014-06-27
AU2012334074A1 (en) 2014-05-01
IL232358A0 (en) 2014-07-01
JP2014534976A (ja) 2014-12-25
TW201326153A (zh) 2013-07-01
WO2013068470A1 (en) 2013-05-16
AR088801A1 (es) 2014-07-10
GT201400089A (es) 2015-09-30
NZ623727A (en) 2016-06-24
KR20140097318A (ko) 2014-08-06
CL2014001212A1 (es) 2014-11-28
MX2014005714A (es) 2014-09-04
US9273068B2 (en) 2016-03-01

Similar Documents

Publication Publication Date Title
HK1201519A1 (zh) 磷酸二酯酶第 型的抑制劑
SG10201605196PA (en) Novel Inhibitor Compounds Of Phosphodiesterase Type 10A
HK1222647A1 (zh) 激酶抑制劑
EP2710007A4 (en) Kinase Inhibitors
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
IL228103A0 (en) Amino-quinolines as kinase inhibitors
GB201016880D0 (en) Phosphodiesterase inhibitors
ZA201309150B (en) Derivatives of 1-phenyl-2-pyridinyl- alkyl alcohols as phosphodiesterase inhibitors
IL229028A0 (en) Kinase inhibitors
EP2685992A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
HK1199873A1 (zh) 激酶抑制劑
HK1199252A1 (zh) -活化酶的抑制劑
HK1201523A1 (zh) 可用作 型磷酸二酯酶的抑制劑的雜環甲酰胺類
HK1206728A1 (zh) 型磷酸二酯酶之新型抑制劑化合物
HK1211581A1 (zh) 新的磷酸二酯酶 型的抑制劑化合物
HK1211284A1 (zh) 磷酸二酯酶 型的抑制劑化合物
GB201120474D0 (en) Inhibitors